

2025 American Society of Clinical
Oncology Annual Meeting

Servier Pharmaceuticals Sponsored Abstracts

ABSTRACTS

For full abstracts please visit the ASCO website



Date & Time

Saturday May 31, 2025
9:00 a.m. – 12:00 p.m. CDT

Saturday May 31, 2025
9:00 a.m. – 12:00 p.m. CDT

Sunday June 1, 2025
9:00 a.m. – 12:00 p.m. CDT

Title

A Phase 1b/2, Safety Lead-in and Dose-Expansion Trial of Ivosidenib plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Patients with Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation.

Phase 3 Study of Ivosidenib vs Placebo in Locally Advanced or Metastatic IDH1-Mutant Conventional Chondrosarcoma Untreated or Previously Treated with 1 Systemic Treatment Regimen (CHONQUER).

Phase 3 Study of Either Ivosidenib Monotherapy or Azacitidine Monotherapy in Patients With IDH1 Mutant Myelodysplastic Syndromes Who Are Hypomethylating Agent Naive (PyramIDH).

Presentation

Poster Presentation
James J. Harding, MD
Memorial Sloan Kettering Cancer Center

Poster Presentation
Andrew J. Wagner, MD, PhD
Dana-Farber Cancer Institute

Poster Presentation
Valeria Santini, MD, PhD
Universitaria Careggi, University of Florence